Frazier Financial Advisors LLC Sells 708 Shares of Smith & Nephew plc (NYSE:SNN)

Frazier Financial Advisors LLC cut its position in Smith & Nephew plc (NYSE:SNN) by 37.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,190 shares of the medical equipment provider’s stock after selling 708 shares during the period. Frazier Financial Advisors LLC’s holdings in Smith & Nephew were worth $29,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in SNN. Charles Schwab Investment Management Inc. grew its stake in shares of Smith & Nephew by 29.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 27,199 shares of the medical equipment provider’s stock valued at $847,000 after acquiring an additional 6,164 shares in the last quarter. Stifel Financial Corp bought a new stake in Smith & Nephew in the 3rd quarter valued at about $1,258,000. Maverick Capital Ltd. bought a new stake in Smith & Nephew in the 3rd quarter valued at about $2,086,000. Blue Trust Inc. grew its position in shares of Smith & Nephew by 26.0% during the 4th quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider’s stock worth $144,000 after purchasing an additional 1,213 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Smith & Nephew by 31.8% during the fourth quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider’s stock worth $73,000 after purchasing an additional 718 shares during the period. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew Price Performance

Shares of NYSE:SNN opened at $28.42 on Friday. Smith & Nephew plc has a one year low of $23.65 and a one year high of $31.72. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11. The company has a market cap of $12.43 billion, a price-to-earnings ratio of 13.16, a PEG ratio of 1.26 and a beta of 0.83. The firm has a 50 day simple moving average of $27.07 and a 200 day simple moving average of $27.02.

Smith & Nephew Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.447 per share. This is a boost from Smith & Nephew’s previous semi-annual dividend of $0.29. This represents a dividend yield of 2.5%. The ex-dividend date is Friday, March 28th. Smith & Nephew’s payout ratio is 41.20%.

Analyst Ratings Changes

A number of analysts have recently weighed in on SNN shares. Canaccord Genuity Group reiterated a “hold” rating and set a $27.00 target price on shares of Smith & Nephew in a research report on Monday, March 17th. StockNews.com upgraded shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 26th. Finally, UBS Group lowered shares of Smith & Nephew from a “buy” rating to a “neutral” rating in a report on Wednesday, March 12th. Four research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $27.00.

Smith & Nephew Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.